This Article Full Text Full Text (PDF) All Versions of this Article: chest.07-1694v1 133/3/646    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Article Archive Download to citation manager Google Scholar Articles by van Beers, E. J. PubMed PubMed Citation Articles by van Beers, E. J.

Large and Medium-Sized Pulmonary Artery Obstruction Does Not Play a Role of Primary Importance in the Etiology of Sickle-Cell Disease-Associated Pulmonary Hypertension^*

Eduard J. van Beers, MD; Berthe L. F. van Eck-Smit, MD, PhD; Melvin R. Mac Gillavry, MD, PhD; Charlotte F. J. van Tuijn, RN; Joost W. J. van Esser, MD, PhD; Dees P. M. Brandjes, MD, PhD; Mies C. Kappers-Klunne, MD, PhD; Ashley J. Duits, MS, PhD; Bart J. Biemond, MD, PhD; John-John B. Schnog, MD, PhD; on Behalf of the CURAMA Study Group

^* From the Department of Hematology (Drs. van Beers, van Tuijn, and Biemond), Academic Medical Center, Amsterdam, the Netherlands; Department of Nuclear Medicine (Dr. van Eck-Smit), Academic Medical Center, Amsterdam, the Netherlands; Department of Cardiology (Dr. Mac Gillavry), Slotervaart Hospital, Amsterdam, the Netherlands; Department of Hematology (Drs. van Esser and Kappers-Klunne), Erasmus Medical Center, Rotterdam, the Netherlands; Department of Internal Medicine (Dr. Brandjes and Schnog), Slotervaart Hospital, Amsterdam, the Netherlands; and The Red Cross Blood Bank Foundation (Dr. Duits), Curaçao, the Netherlands Antilles. The CURAMA study group is a collaborative effort studying SCD in the Netherlands Antilles and the Netherlands. Participating centers include The Red Cross Blood Bank Foundation, Curaçao, the Netherlands Antilles; The Antillean Institute for Health Research, Curaçao, the Netherlands Antilles; The Department of Internal Medicine, Slotervaart Hospital, Amsterdam, the Netherlands; the Department of Vascular Medicine and the Department of Hematology, Academic Medical Center, Amsterdam, the Netherlands; the Department of Hematology, Erasmus Medical Center, Rotterdam, the Netherlands; the Department of Pathology, Groningen University Hospital, Groningen, the Netherlands; the Department of Internal Medicine, the Laboratory of Clinical Thrombosis and Hemostasis, and the Cardiovascular Research Institute, Academic Hospital Maastricht, Maastricht, the Netherlands.

Correspondence to: John-John B. Schnog, MD, PhD, Department of Hematology, Erasmus Medical Center, s-Gravendijkwal 230, 3015 CE, Rotterdam, the Netherlands; e-mail: jbschnog{at}mac com

Abstract

Background: Pulmonary hypertension (PHT) occurs in approximately 30% of adult patients with sickle-cell disease (SCD) and is a risk factor for early death. The potential role of pulmonary artery obstruction, whether due to emboli or in situ thrombosis, in the etiology of SCD-related PHT is unknown.

Methods: Consecutive SCD patients were screened for PHT (defined as a tricuspid regurgitant jet flow velocity 2.5 m/s) employing echocardiography and were evaluated for pulmonary artery obstruction with ventilation-perfusion (VQ) scintigraphy.

Results: Fifty-three HbSS, 6 HbSβ⁰-thalassemia, 20 HbSC, and 6 HbSβ⁺-thalassemia patients were included. The overall prevalence of PHT was 41% in HbSS/HbSβ⁰-thalassemia patients and 13% in HbSC/HbSβ⁺-thalassemia patients. High-probability VQ defects (Prospective Investigation of Pulmonary Embolism Diagnosis criteria) were detected in two patients, one of whom had PHT. In HbSS/HbSβ⁰-thalassemia patients with PHT, 19 patients (86%), 2 patients (9%), and 1 patient (5%) had low-, intermediate-, or high-probability scan results as compared to 30 patients (97%), 1 patient (3%), and 0 patients (0%) in HbSS/HbSβ⁰-thalassemia patients without PHT (p = 0.31). In HbSC/HbSβ⁺-thalassemia patients with PHT, 3 patients (100%), 0 patients (0%), and 0 patients (0%) had low-, intermediate-, and a high-probability scan as compared to 19 patients (90%), 1 patient (5%), and 1 patient (5%) in HbSC/HbSβ⁺-thalassemia patients without PHT (p = 0.86). There were no statistical differences in irregular distribution of the radiopharmaceutical or nonspecific signs associated with PHT between patients with and without PHT.

Conclusions: Although small pulmonary artery obstruction cannot be excluded, large to medium-sized pulmonary artery obstruction is an unlikely primary causative factor in SCD-related PHT.

Key Words: echocardiography • pulmonary artery obstruction • pulmonary artery thrombosis • pulmonary hypertension • sickle-cell disease • ventilation-perfusion scintigraphy